Literature DB >> 10834812

Clinical and microbiological survey of Serratia marcescens infection during HIV disease.

R Manfredi1, A Nanetti, M Ferri, F Chiodo.   

Abstract

Clinical charts of 2,398 consecutive HIV-infected patients hospitalized over an 8-year period were reviewed retrospectively to identify all cases of Serratia infection and to evaluate the occurrence and outcome of these cases according to several epidemiological. clinical, and laboratory parameters. Seventeen of 2,398 (0.71%) patients developed Serratia marcescens infections: nine had septicaemia, six had pneumonia, one had a lymph node abscess, and one had cellulitis. All patients were severely immunocompromised, as evidenced by a mean CD4+ lymphocyte count of < 70 cells/microl and a frequent diagnosis of AIDS (13 patients). When compared with other disease localizations, septicaemia was related to a significantly lower CD4+ cell count and a more frequent occurrence of neutropaenia. Antibiotic, corticosteroid, or cotrimoxazole treatment was frequently carried out during the month preceding disease onset. Hospital-acquired Serratia spp. infection was more frequent than community-acquired infection and was significantly related to AIDS, neutropaenia, and sepsis. Antimicrobial sensitivity testing showed complete resistance to ampicillin and cephalothin but elevated susceptibility to ureidopenicillins, second- and third-generation cephalosporins, aminoglycosides, quinolones, and cotrimoxazole. An appropriate antimicrobial treatment attained clinical and microbiological cure in all cases, in absence of related mortality or relapses. Since only 13 episodes of HIV-associated Serratia spp. infection have been described until now in nine different reports (7 patients with pneumonia, 3 with sepsis, 1 with endophthalmitis, 1 with perifolliculitis, and 1 with cholecystitis), our series represents the largest one dealing with Serratia marcescens infection during HIV disease. Serratia marcescens may be responsible for appreciable morbidity among patients with HIV disease, especially when a low CD4 + cell count, neutropaenia, and hospitalization are present. The clinician and the microbiologist facing a severely immunocompromised HIV-infected patient with a suspected bacterial disease should consider the Serratia spp. organisms. In fact, a rapid diagnosis and an adequate and timely treatment can avoid disease relapses and mortality.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10834812     DOI: 10.1007/s100960050471

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  [Life-threatening necrotizing fasciitis colli caused by Serratia marcescens].

Authors:  M Meisel; H-J Schultz-Coulon
Journal:  HNO       Date:  2009-10       Impact factor: 1.284

2.  Novel tetracycline resistance determinant isolated from an environmental strain of Serratia marcescens.

Authors:  Stuart A Thompson; Elizabeth V Maani; Angela H Lindell; Catherine J King; J Vaun McArthur
Journal:  Appl Environ Microbiol       Date:  2007-02-16       Impact factor: 4.792

3.  Characterization of a cytotoxic factor in culture filtrates of Serratia marcescens.

Authors:  Kent B Marty; Christopher L Williams; Linda J Guynn; Michael J Benedik; Steven R Blanke
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

4.  Serratia marcescens endogenous endophthalmitis in an immunocompetent host.

Authors:  Muhammad Memon; Vasant Raman
Journal:  BMJ Case Rep       Date:  2016-01-20

5.  Down in the pond: Isolation and characterization of a new Serratia marcescens strain (LVF3) from the surface water near frog's lettuce (Groenlandia densa).

Authors:  Ines Friedrich; Bernhard Bodenberger; Hannes Neubauer; Robert Hertel; Rolf Daniel
Journal:  PLoS One       Date:  2021-11-08       Impact factor: 3.240

6.  Design, synthesis and biological evaluation of 1,2,3-triazole based 2-aminobenzimidazoles as novel inhibitors of LasR dependent quorum sensing in Pseudomonas aeruginosa.

Authors:  Singireddi Srinivasarao; Adinarayana Nandikolla; Shashidhar Nizalapur; Tsz Tin Yu; Sravani Pulya; Balaram Ghosh; Sankaranarayanan Murugesan; Naresh Kumar; Kondapalli Venkata Gowri Chandra Sekhar
Journal:  RSC Adv       Date:  2019-09-17       Impact factor: 4.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.